论文部分内容阅读
目的对已融合的人粒细胞-巨噬细胞集落刺激因子基因(GM-CSF)与EB病毒即刻早期基因(BZLF1)进行抗肿瘤活性及免疫学研究。方法建立C57BL/6小鼠肿瘤模型,rBCG注射免疫后采用ELISA检测其特异性抗体,用乳酸脱氢酶法检测特异性CTL,HE染色检测肿瘤组织中的淋巴细胞浸润情况。并对各试验组小鼠成瘤时间、肿瘤大小进行分析,采用t检验方法对重组BCG抗肿瘤效果进行初步分析和评价。结果 rBCG免疫小鼠肿瘤成瘤时间延迟,最迟长达11.9d;肿瘤生长缓慢,生存时间显著延长,平均抑瘤率为82%;rBCG刺激小鼠产生特异性GM-CSF和BZLF1抗体,特异性CTL活性增强;当效靶比(E/T)为40∶1时,CTL杀伤率为(37.25士5.09)%;HE染色镜检肿瘤组织中淋巴细胞浸润。结论重组BCG免疫小鼠能诱导产生特异性体液免疫和细胞免疫,可抑制EB病毒阳性肿瘤细胞生长。
Objective To study the anti-tumor activity and immunological properties of fused human granulocyte-macrophage colony stimulating factor gene (GM-CSF) and Epstein-Barr virus immediate early gene (BZLF1). Methods C57BL / 6 mouse tumor model was established. Specific antibody was detected by ELISA after rBCG injection and specific CTL was detected by lactate dehydrogenase method. Lymphocyte infiltration in tumor tissue was detected by HE staining. The tumor-forming time and tumor size of mice in each experimental group were analyzed. The t-test was used to analyze the anti-tumor effect of recombinant BCG. Results The tumorigenicity of rBCG-immunized mice was delayed for as long as 11.9 days. The tumor growth was slow and the survival time was significantly prolonged with an average inhibition rate of 82%. The rBCG-stimulated mice produced specific GM-CSF and BZLF1 antibodies, CTL activity was enhanced. When the target ratio (E / T) was 40:1, the CTL killing rate was (37.25 ± 5.09)%. Lymphocyte infiltration was observed by HE staining. Conclusion Recombinant BCG immunized mice can induce specific humoral and cellular immunity and inhibit the growth of EBV positive tumor cells.